Saxenda vs Retatrutide: Long-Term Durability of Response

How Each Drug Works and Why Mechanism Predicts Durability

Receptor pharmacology is not just a biochemistry footnote. It directly predicts how much weight a patient loses, how long that loss lasts, and what happens when the drug is stopped.

Saxenda is a GLP-1 receptor agonist dosed at 3 mg subcutaneously once daily. It slows gastric emptying, suppresses appetite through hypothalamic pathways, and modestly increases insulin secretion in a glucose-dependent fashion. The FDA label for liraglutide 3 mg describes the approved indication as chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity.

Retatrutide co-activates three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon. The glucagon receptor component increases energy expenditure by raising basal metabolic rate, adding a thermogenic dimension that single-agonist GLP-1 drugs do not provide. This triple mechanism likely explains the substantially larger weight reductions seen in early trials.

GLP-1 Mono-Agonism and Its Ceiling Effect

Single-target GLP-1 agonism has a practical ceiling. Appetite suppression through the arcuate nucleus can only go so far before counter-regulatory hunger signals reassert themselves. Long-term data on liraglutide show that weight plateaus at roughly 6 to 12 months, and some patients experience modest regain even while remaining on therapy, a phenomenon sometimes called "breakthrough weight regain."

Triple Agonism and the Thermogenic Add-On

Adding glucagon receptor agonism to GIP/GLP-1 co-agonism pushes weight loss through a second physiological door: energy expenditure. Preclinical and Phase 2 human data suggest that the glucagon component contributes meaningfully to fat oxidation in a way that is additive to the appetite-suppression effect. This is one reason retatrutide's weight-loss curve did not appear to plateau by week 48 in the Phase 2 trial.

The Core Trial Evidence: What the Data Actually Show

SCALE Obesity and Prediabetes (Saxenda)

The definitive long-term Saxenda trial is the SCALE Obesity and Prediabetes study, published in the New England Journal of Medicine in 2015. In this randomized, double-blind, placebo-controlled trial of 3,731 adults without type 2 diabetes, participants received liraglutide 3 mg or placebo for 56 weeks, followed by a 12-week off-drug observation period [1].

Key results at week 56:

• Mean weight loss: 8.0% from baseline in the liraglutide group vs. 2.6% in the placebo group (P<0.001) [1].
• 63.2% of liraglutide-treated patients lost at least 5% of body weight, compared with 27.1% on placebo [1].
• 33.1% lost at least 10% of body weight vs. 10.6% on placebo [1].

These are the numbers clinicians quote most. What gets less attention is the 12-week withdrawal phase: patients who stopped liraglutide regained an average of 2.8 kg within 12 weeks, while those who continued the drug maintained or continued to lose weight. That asymmetry underlines that Saxenda is a long-term, ongoing therapy, not a short course.

Retatrutide Phase 2 (Jastreboff et al., NEJM 2023)

The Phase 2 dose-ranging trial of retatrutide, conducted by Jastreboff and colleagues and published in the New England Journal of Medicine in June 2023, enrolled 338 adults with obesity (BMI 30 to 50) or overweight with at least one comorbidity and randomized them to one of five retatrutide doses or placebo for 48 weeks [2].

Results were notable:

• The highest-dose group (12 mg weekly) achieved a mean weight loss of 24.2% at 48 weeks [2].
• The 8 mg weekly group lost a mean of 22.8% [2].
• Placebo participants lost 2.1% [2].
• Critically, the weight-loss curve had not plateaued by week 48 in the highest-dose cohort, suggesting that peak efficacy had not yet been reached.

As the authors stated directly: "Retatrutide treatment resulted in substantial reductions in body weight, with the largest reductions in the groups that received the 8-mg or 12-mg doses" [2]. That observation, combined with the non-plateauing curve, distinguishes retatrutide from every approved GLP-1 monotherapy in the current durability literature.

Durability Head-to-Head: Weight Loss Over Time

Durability means more than peak efficacy. It means: how much weight does a patient maintain at 1 year, 2 years, and beyond, and what happens when the drug is paused or stopped?

One-Year Comparison

At 52 to 56 weeks, the approximate comparison looks like this:

| Drug | Trial | N | Mean % Weight Loss | % Losing >10% | |---|---|---|---|---| | Liraglutide 3 mg | SCALE Obesity [1] | 2,487 active | 8.0% | 33.1% | | Retatrutide 12 mg | Phase 2 [2] | 67 | 24.2% at 48 wk | ~82% (estimated) |

The Phase 2 retatrutide data are not directly comparable to SCALE because the populations, doses, and trial designs differ. Still, the magnitude difference (roughly 16 percentage points of body weight) is large enough to be clinically meaningful even after adjusting for design differences.

Plateau Timing and the Weight-Loss Trajectory

Saxenda recipients in SCALE Obesity reached their nadir weight around weeks 24 to 32, after which the curve flattened. Retatrutide recipients at 8 and 12 mg had not reached their nadir by week 48. Phase 3 data from the ongoing retatrutide program will clarify whether this trajectory continues through 72 or 104 weeks.

Regain After Discontinuation

Both drugs share a fundamental property of anti-obesity pharmacotherapy: stopping the drug leads to weight regain. The SCALE data showed 2.8 kg regain within 12 weeks of stopping liraglutide [1]. Comparable discontinuation data for retatrutide at the 48-week mark are not yet published from Phase 3, but the Phase 2 design did not include a structured withdrawal phase. Based on GLP-1 class pharmacology reviewed in the NIH NIDDK literature on weight regain, regain after GLP-1-class drug discontinuation is a consistent finding across agents. Retatrutide patients who have lost 24% of body weight face a larger absolute regain risk simply because more weight was lost.

Real-World Saxenda Durability: What Happens Outside Trials

Randomized trials enroll motivated, protocol-adherent participants. Real-world Saxenda data show a more modest picture.

Adherence and Persistence

A 2022 analysis of insurance claims data estimated that fewer than 30% of patients who fill an initial Saxenda prescription are still filling it at 12 months, a persistence rate far lower than trial completion rates. Low persistence translates directly to lower real-world durability because weight regain accelerates once the drug is stopped.

Non-Responder Identification

The FDA-approved Saxenda prescribing label recommends evaluating response at 16 weeks. Patients who have not lost at least 4% of body weight by week 16 are described as unlikely to achieve clinically meaningful long-term weight loss and should discontinue. This threshold is a practical durability screen: it allows early identification of non-responders before months of ineffective therapy accumulate.

Tolerability and Its Impact on Long-Term Use

Nausea is the most common adverse effect of liraglutide 3 mg, affecting roughly 39% of participants in SCALE Obesity [1]. Gastrointestinal tolerability is a durability variable. Patients who cannot tolerate the dose needed for efficacy will not achieve durable outcomes regardless of pharmacological potential. In the retatrutide Phase 2 trial, nausea affected approximately 43 to 47% of participants in the highest-dose groups, suggesting that GI tolerability is a shared limitation rather than a differentiator [2].

Switching From Saxenda to Retatrutide: Clinical Considerations

Switching from liraglutide 3 mg to retatrutide is not yet a routine clinical pathway because retatrutide is not FDA-approved as of early 2025. Phase 3 trials are ongoing under Eli Lilly's development program. Still, the switching question is clinically relevant now because patients and prescribers need a framework for when to escalate.

Who Is a Candidate for the Switch?

A reasonable clinical framework for considering a switch, once retatrutide becomes available, would include patients who meet at least one of the following:

• Lost <5% of body weight after 16 or more weeks on maximally tolerated Saxenda.
• Initially responded to Saxenda but experienced plateau or regain after 6 to 12 months despite adherence.
• Have a baseline BMI >40 where the incremental weight loss from a triple agonist would provide meaningful comorbidity benefit (for example, reducing the probability of needing bariatric surgery).
• Have type 2 diabetes or prediabetes where additional metabolic benefit from GIP and glucagon receptor co-activation may be important.

Washout and Transition Timing

Because liraglutide has a half-life of approximately 13 hours, a washout period of two to three days is pharmacologically sufficient before starting a new GLP-1-class agent. However, clinicians should assess whether appetite suppression has diminished sufficiently before titrating a new agent, to avoid additive GI side effects during the early dose-escalation phase. The Endocrine Society's 2015 pharmacotherapy guideline for obesity recommends that switching between obesity medications be accompanied by reassessment of cardiovascular risk factors and metabolic markers.

What the Phase 3 Data Will Need to Show

For the switch to become guideline-supported, Phase 3 retatrutide trials will need to demonstrate:

1. Durability of the 20 to 24% weight loss beyond 72 weeks.
2. A cardiovascular outcomes trial (CVOT) with neutral or beneficial results.
3. Tolerability in patients with prior GLP-1 exposure.

Liraglutide's CVOT, LEADER, demonstrated a significant reduction in major adverse cardiovascular events in patients with type 2 diabetes, a bar that retatrutide will likely need to clear for broad prescribing confidence. The LEADER trial results are available on PubMed.

Safety Profiles and Long-Term Tolerability Comparison

Both agents carry class-related risks that affect long-term use decisions.

Saxenda (Liraglutide 3 mg) Safety

The established long-term safety profile of liraglutide 3 mg includes:

• Gastrointestinal events (nausea, diarrhea, constipation): most common, usually transient [1].
• Black box warning for thyroid C-cell tumors, observed in rodents. The clinical relevance in humans remains uncertain per the FDA label.
• Pancreatitis: rare but documented. The SCALE program reported no significant increase versus placebo.
• Gallbladder disease: rapid weight loss with any agent increases cholelithiasis risk.

The drug has over a decade of post-marketing surveillance data, giving it a durability of safety evidence that retatrutide has not yet accumulated.

Retatrutide Safety (Phase 2 Data)

In the Phase 2 trial, the most common adverse events were nausea (43 to 47% at higher doses), vomiting, and diarrhea [2]. No new safety signals outside the GLP-1 class were identified in that 48-week dataset. Longer-term and larger-population safety data are pending from Phase 3.

The glucagon receptor component raises a theoretical concern about hepatic glucose output and effects on bone metabolism. These will require monitoring in Phase 3 and post-marketing surveillance. The NIH's ClinicalTrials.gov registry lists multiple ongoing Phase 3 studies for retatrutide that include these endpoints.

Who Should Stay on Saxenda in 2025?

Given that retatrutide is not yet approved, the practical question for most patients is whether Saxenda remains the right agent now, and whether a future switch to retatrutide would offer meaningful additional benefit.

Saxenda remains a reasonable choice for patients who:

• Are achieving at least 5% weight loss at 16 weeks and tolerating the drug well.
• Have a documented cardiovascular history where liraglutide's LEADER CVOT data provide reassurance.
• Prefer a once-daily regimen over once-weekly (retatrutide in Phase 2 was weekly).
• Have cost or access constraints, since Saxenda has broader insurance coverage than agents still in development.

For patients who have not responded to Saxenda at 16 weeks, the Endocrine Society guideline explicitly supports discontinuation and consideration of alternative agents. With the current approved field, the next-step options include semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound). In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced mean weight loss of 20.9% at 72 weeks [see the SURMOUNT-1 publication on PubMed], which approaches retatrutide Phase 2 performance and is already FDA-approved.

Key Takeaways for Clinicians

The durability gap between Saxenda and retatrutide, based on available Phase 2 evidence, is substantial: roughly 8% mean weight loss versus 24% at 48 to 56 weeks. The mechanisms explain the difference. Saxenda's single-receptor approach has a ceiling; retatrutide's triple agonism adds a thermogenic component that single agents lack.

For patients on Saxenda today, the 16-week response assessment remains the most actionable durability checkpoint: patients who have not lost 4% or more of body weight by then should switch to a more effective available agent. Retatrutide's Phase 3 results, expected in 2025 to 2026, will determine whether that agent becomes the next escalation option.

Until Phase 3 data confirm durability beyond 48 weeks and a CVOT is completed, retatrutide should be viewed as a highly promising agent with exceptional short-term Phase 2 data, not yet a confirmed long-term durability solution.